Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
NCT05531786
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
50
Enrollment
NIH
Sponsor class
Conditions
Graft vs Host Disease
Interventions
DRUG:
Pacritinib
Sponsor
National Cancer Institute (NCI)